June 24th 2025, 5:00pm
Dr. Rita Mukhtar sits down for a conversation with Dr. Joshua Sabari to discuss the potential use of ctDNA to guide breast cancer therapy.
June 23rd 2025, 1:00pm
Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting.
June 22nd 2025, 2:00pm
The 2025 ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple myeloma and lymphoma.
June 20th 2025, 4:00pm
Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the REZILIENT-1 and NeoADAURA trials.
June 19th 2025, 7:00pm
Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.
June 19th 2025, 4:00pm
Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.
June 18th 2025, 4:26pm
Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.
June 18th 2025, 1:00pm
For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.
June 17th 2025, 1:00pm
Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, according to experts.
June 16th 2025, 8:00pm
Dr. Joshua K. Sabari and Jackie Herigodt sat down to discuss the importance of knowing a patient beyond their cancer diagnosis.
How Multidisciplinary Care Impacts Prostate Cancer Treatment
A New Frontier in Melanoma Treatment
Reflections After Nine Years as a Bladder Cancer Survivor
Zegfrovy FDA Approved for EGFR Exon 20 Non-Small Cell Lung Cancer